TNF-α blockade is ineffective in animal models of established polycystic kidney disease

BMC Nephrology

Saurabh Saha¹  Jeffrey Roix¹ 

[1] Biomed Valley Discoveries Inc, 4520 Main Street, Suite 1650, MO 64111, Kansas City, USA

关键词: PKD2;    PKHD1;    TNF-α;    Etanercept;    Polycystic kidney disease;   

Others  :  1082806
DOI  :  10.1186/1471-2369-14-233

 received in 2013-06-28, accepted in 2013-10-14,  发布年份 2013

【 摘 要 】

Background

Given the large medical burden of polycystic kidney disease (PKD) and recent clinical trial failures, there is a need for novel, safe and effective treatments for the disorder.

Methods

In PCK rat and PKD2^(ws25/w183) mouse models, entanercept was administered once every three days at 5 or 10 mg/kg, once daily. Mozavaptan was administered as a pilot control, provided continuously via milled chow at 0.1%. Animals were assessed for measures of pharmacodynamic response, and improvements in measures of polycystic kidney disease.

Results

Entanercept treatment modulated inflammatory markers, but provided limited therapeutic benefit in multiple animal models of established polycystic kidney disease. Kidney weight, cyst burden and renal function markers remained unchanged following administration of etanercept at various dose levels and multiple treatment durations.

Conclusions

While it remains possible that TNF-α inhibition may be effective in truly preventative settings, our observations suggest this pathway is less likely to exhibit therapeutic or disease-modifying efficacy following the standard clinical diagnosis of disease.

【 授权许可】

   
2013 Roix and Saha; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Grantham JJ: Clinical practice Autosomal dominant polycystic kidney disease. N Engl J Med 2008, 359(14):1477-1485.
• [2]Delmas P: Polycystins: from mechanosensation to gene regulation. Cell 2004, 118(2):145-148.
• [3]Weimbs T: Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. Am J Physiol Renal Physiol 2007, 293(5):F1423-F1432.
• [4]Wang X, Gattone V, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005, 16(4):846-851.
• [5]Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006, 21(3):598-604.
• [6]Meijer E, Gansevoort RT, de Jong PE, et al.: Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant 2011, 26(8):2445-2453.
• [7]Watnick T, Germino GG: mTOR inhibitors in polycystic kidney disease. N Engl J Med 2010, 363(9):879-881.
• [8]Schrier RW: Randomized intervention studies in human polycystic kidney and liver disease. J Am Soc Nephrol 2010, 21(6):891-893.
• [9]Serra AL, Poster D, Kistler AD, et al.: Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010, 363(9):820-829.
• [10]Scott DL, Kingsley GH: Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355(7):704-712.
• [11]Danese S, Fiocchi C: Ulcerative colitis. N Engl J Med 2011, 365(18):1713-1725.
• [12]Li X, Magenheimer BS, Xia S, et al.: A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 2008, 14(8):863-868.
• [13]Pei Y, Obaji J, Dupuis A, et al.: Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009, 20(1):205-212.
• [14]Katsuyama M, Masuyama T, Komura I, Hibino T, Takahashi H: Characterization of a novel polycystic kidney rat model with accompanying polycystic liver. Exp Anim 2000, 49(1):51-55.
• [15]Renken C, Fischer DC, Kundt G, Gretz N, Haffner D: Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol Dial Transplant 2011, 26(1):92-100.
• [16]Chen G, Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science 2002, 296(5573):1634-1635.
• [17]Wu G, D’Agati V, Cai Y, et al.: Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 1998, 93(2):177-188.